249 related articles for article (PubMed ID: 28942418)
21. A descriptive analysis of postmarketing requirement studies and clinical trials.
Choi L; Etchey B; Billings M; Lee C; Weil KM; Boxwell D; Edelberg H
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5725. PubMed ID: 37994284
[TBL] [Abstract][Full Text] [Related]
22. FDAAA legislation is working, but methodological flaws undermine the reliability of clinical trials: a cross-sectional study.
Marin Dos Santos DH; Atallah ÁN
PeerJ; 2015; 3():e1015. PubMed ID: 26131374
[TBL] [Abstract][Full Text] [Related]
23. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
Deane BR; Porkess S
Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
[TBL] [Abstract][Full Text] [Related]
24. Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA.
Talebi R; Redberg RF; Ross JS
Trials; 2020 Jul; 21(1):675. PubMed ID: 32703252
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012.
Rawal B; Deane BR
Curr Med Res Opin; 2015; 31(7):1431-5. PubMed ID: 25942525
[TBL] [Abstract][Full Text] [Related]
26. Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe.
Rawal B; Deane BR
Curr Med Res Opin; 2014 Mar; 30(3):395-405. PubMed ID: 24168052
[TBL] [Abstract][Full Text] [Related]
27. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013.
Deane BR; Sivarajah J
Curr Med Res Opin; 2017 Mar; 33(3):473-478. PubMed ID: 27869482
[TBL] [Abstract][Full Text] [Related]
28. Evaluating publication bias for clinical trials supporting new dermatologic drug approvals from 2003 to 2018.
Ravichandran S; Mulligan KM; Ezaldein HH; Scott JF
Arch Dermatol Res; 2023 May; 315(4):831-838. PubMed ID: 36333459
[TBL] [Abstract][Full Text] [Related]
29. Research without results: inadequate public reporting of clinical trial results.
Gopal RK; Yamashita TE; Prochazka AV
Contemp Clin Trials; 2012 May; 33(3):486-91. PubMed ID: 22342449
[TBL] [Abstract][Full Text] [Related]
30. Clinical trial registration and reporting: a survey of academic organizations in the United States.
Mayo-Wilson E; Heyward J; Keyes A; Reynolds J; White S; Atri N; Alexander GC; Omar A; Ford DE;
BMC Med; 2018 May; 16(1):60. PubMed ID: 29716585
[TBL] [Abstract][Full Text] [Related]
31. Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles.
Pranić S; Marušić A
J Clin Epidemiol; 2016 Feb; 70():26-37. PubMed ID: 26226103
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials transparency and the Trial and Experimental Studies Transparency (TEST) act.
Logvinov I
Contemp Clin Trials; 2014 Mar; 37(2):219-24. PubMed ID: 24440100
[TBL] [Abstract][Full Text] [Related]
33. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
Cohen K; Cormier JW; Davar MV
J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
[No Abstract] [Full Text] [Related]
34. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
Kesselheim AS; Mello MM
Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
[TBL] [Abstract][Full Text] [Related]
35. E-cigarette manufacturers' compliance with clinical trial reporting expectations: a case series of registered trials by Juul Labs.
DeVito NJ; Drysdale H; McKee M; Goldacre B
Tob Control; 2023 Jan; 32(1):60-66. PubMed ID: 34127550
[TBL] [Abstract][Full Text] [Related]
36. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
37. Reporting Compliance and Factors Influencing Timeliness of Stroke-Related Trial Results on ClinicalTrials.gov.
Cwajna M; Hamouda AM; Kendall N; Ghozy S; Elder BD; Kallmes DF
Transl Stroke Res; 2024 Jun; ():. PubMed ID: 38831158
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Compliance With Legal Requirements Under the FDA Amendments Act of 2007 for Timely Registration of Clinical Trials, Data Verification, Delayed Reporting, and Trial Document Submission.
DeVito NJ; Goldacre B
JAMA Intern Med; 2021 Aug; 181(8):1128-1130. PubMed ID: 34028509
[TBL] [Abstract][Full Text] [Related]
39. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
40. Prospective registration trends, reasons for retrospective registration and mechanisms to increase prospective registration compliance: descriptive analysis and survey.
Hunter KE; Seidler AL; Askie LM
BMJ Open; 2018 Mar; 8(3):e019983. PubMed ID: 29496896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
